InnoCare’s Oral Psoriasis Drug ICP‑488 Hits Phase III Target, Paving Path to Regulatory FilingTip Ranks·2 days ago, 04:37 AM09969-0.78%688428+0.70%
Platformization of the Physical World: Redefining Value Chains in HK EquitiesGlobal Report·Jul 19 at 04:13 AM06810+0.26%02191+1.14%
Hong Kong's Cross-Sector Signals: From AI Infrastructure to Global BiopharmaGlobal Report·Jul 18 at 04:12 AM01686+1.31%02858+4.55%
UBS Reaffirms Their Buy Rating on InnoCare Pharma Ltd. (9969)Tip Ranks·Jul 17 at 04:55 AM09969-0.78%RANK-1.71%
InnoCare says Phase II vitiligo trial of TYK2 inhibitor soficitinib meets primary endpoint at Week 24PUBT·Jul 16 at 03:51 AM09969-0.78%688428+0.70%
InnoCare’s TYK2 Inhibitor Soficitinib Hits Phase III Goal in Atopic DermatitisTip Ranks·Jul 15 at 06:07 AM688428+0.70%09969-0.78%
InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLLUnusual Whales·Jul 14 at 06:25 AM09969-0.78%688428+0.70%
InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in ChinaGlobeNewswire·Jul 5 at 08:00 PM09969-0.78%688428+0.70%
InnoCare Pharma files HKEX next-day return, reports 2,418,300-share capital increasePUBT·Jun 26 at 04:12 AM09969-0.78%
InnoCare Pharma hits 52-week low, falls 2% in Hong Kong tradingHK Stock Market Update·Jun 15 at 09:09 PM09969-0.78%688428+0.70%
InnoCare Presents Positive Phase 2b Data For Orelabrutinib In Treating Lupusnasdaq·Jun 5 at 10:10 AM09969-0.78%688428+0.70%
